Liver Cancer Survival: A Real World Observation of 45 Years with 32,556 Cases

Abstract

Background and Aims: To explore the long-term trend of liver cancer survival, based on the real-world data (RWD) in the past 45 years from a population-based cancer registry, in Qidong, China. Methods: A number of 32,556 patients with liver cancer were registered during the period of 1972 to 2016. Mixed methods by active and passive follow-up were performed. Life table method was employed for survival analysis by SPSS22 software. Wilcoxon (Gehan) statistics was considered as a significant test. Relative survival was calculated by using SURV software, and its annual percent change (APC) was estimated by the Joinpoint Regression Program. Results: The overall observed survival (OS) rates of 1-, 5-, 10-, and 20-year rates from the data series were 18.51%, 6.28%, 4.03%, and 2.84%, and their relative survival (RS) rates were 18.88%, 6.95%, 4.96%, and 4.49%, respectively. For 24,338 male cases, the 5-year OS and RS rates were 5.93% and 6.54%, and for 8218 female cases, 7.34% and 8.15%, respectively, with P values less than 0.01. Survival rates of liver cancer from three 15-year periods of 1972-1986, 1987-2001, and 2002-2016 have increased significantly, with 5-year OS rates of 2.02%, 4.40%, and 10.76%, 5-year RS rates of 2.18%, 4.83%, and 12.18%; 10year OS and RS rates of 0.95%, 3.00%, and 7.02%, vs 1.13%, 3.65%, and 8.96%, respectively, showing a very significant upward trend (P<0.01). There are significant differences among age groups (P<0.01): those aged 55-64 demonstrated the best OS and RS rates of 5-year, being 8.44% and 9.09%, respectively. Conclusion: There are significant gender and age differences in the survival rate of liver cancer in Qidong. RWD indicates the relative lower survival rate of liver cancer in this area, but great improvement has been achieved over the past decades.

An Analysis of Microwave Ablation Parameters for Treatment of Liver Tumors from the 3D-IRCADb-01 Database

“…The most prevalent type of liver cancer is Hepatocellular carcinoma (HCC) or hepatoma with a median survival time of fewer than six months if untreated, and a five-year survival rate of only 5–9% from the time of diagnosis [ 11 , 12 ]. Since HCC is the sixth most common cancer and the second most common cause of cancer mortality worldwide, establishing an efficient treatment for this type of cancer has never been more urgent [ 13 , 14 , 15 , 16 , 17 , 18 ].…”

Development and Validation of a Novel Model to Predict Regional Lymph Node Metastasis in Patients With Hepatocellular Carcinoma

“…Hepatocellular carcinoma (HCC) accounts for approximately 85%-90% of primary liver cancer and has been a heavy global health burden in the past few decades. According to a US national survey, HCC is the 5 th and 7 th cancer type of the estimated new cancer deaths for males and females, respectively (1)(2)(3)(4)(5)(6). Due to cytological variants, HCC has several rare pathological subtypes, including fibrolamellar, clear cell, spindle cell, scirrhous and pleomorphic.…”

Using Period Analysis to Timely Assess and Predict 5-Year Relative Survival for Liver Cancer Patients From Taizhou, Eastern China

“…First, the calculation period was 8 years earlier for the report of 19.1% during 2005–2010 for Zhejiang province compared to our data (2014–2018). It is common sense that the survival of liver cancer patients shall be improved along with the progress of science and technology and the improvement of treatment over recent years (8 years later for our data) ( 12 – 16 ), as well as the implementation of early screening programs for liver cancer patients ( 17 – 20 ) and the accessibility of medical insurance systems for the local population. Second, the report of 19.1% for 2005–2010 was calculated by the cohort approach, which shall be significantly lower compared to the survival estimate calculated by the period approach, as confirmed by our group for the 5-year RS during 2009–2013 ( 9 ).…”

“…Firstly, while advances in clinical treatment approaches have been beneficial to liver cancer patient survival, surgical resection remains the most beneficial treatment associated with improvements in survival for the liver cancer patient ( 12 – 15 ). Second, B-ultrasound and alpha fetoprotein (AFP)-based screening approaches have been used in routine physical examinations over recent years, enabling the potential detection of abnormalities in individuals who are otherwise largely asymptomatic ( 18 – 20 ). Therefore, substantial improvements in survival for the liver cancer patient over the past 10 years could be likely attributable to improvements in surveillance, screening, and early detection.…”